HUP0302194A2 - A kemokin-mutánsok a sclerosis multiplex kezelésében - Google Patents

A kemokin-mutánsok a sclerosis multiplex kezelésében

Info

Publication number
HUP0302194A2
HUP0302194A2 HU0302194A HUP0302194A HUP0302194A2 HU P0302194 A2 HUP0302194 A2 HU P0302194A2 HU 0302194 A HU0302194 A HU 0302194A HU P0302194 A HUP0302194 A HU P0302194A HU P0302194 A2 HUP0302194 A2 HU P0302194A2
Authority
HU
Hungary
Prior art keywords
treatment
multiple sclerosis
chemokine mutants
chemomutants
rantes
Prior art date
Application number
HU0302194A
Other languages
English (en)
Inventor
Marie Kosco-Vilbois
Amanda Proudfoot
Timothy N.C. Wells
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of HUP0302194A2 publication Critical patent/HUP0302194A2/hu
Publication of HUP0302194A3 publication Critical patent/HUP0302194A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgyát olyan kemokimutánsok képezik, amelyekszerkezetében a 40-es hurok kationos helyén legalább két mutációttartalmaznak, és amelyek a vadtípusú molekulával összehasonlítvacsökkent GAG-kötő aktivitást mutatnak. Különösképpen, azt figyelhetőmeg, hogy az ilyen mutált kemokinek hatékonyak a sclerosis multiplexés/vagy más, a mielinpusztulással járó betegségek kezelésében. Aháromszoros mutációt hordozó RANTES az a vegyület, amely a legjobberedményeket mutatta. Ó
HU0302194A 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis HUP0302194A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00121665 2000-10-04
PCT/EP2001/011428 WO2002028419A2 (en) 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
HUP0302194A2 true HUP0302194A2 (hu) 2003-10-28
HUP0302194A3 HUP0302194A3 (en) 2005-12-28

Family

ID=8170011

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302194A HUP0302194A3 (en) 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis

Country Status (31)

Country Link
US (1) US7402303B2 (hu)
EP (1) EP1326628B1 (hu)
JP (1) JP3908165B2 (hu)
KR (1) KR100837898B1 (hu)
CN (1) CN1285381C (hu)
AR (1) AR030854A1 (hu)
AT (1) ATE265222T1 (hu)
AU (2) AU2002215919B2 (hu)
BG (1) BG66137B1 (hu)
BR (1) BR0114407A (hu)
CA (1) CA2423616C (hu)
CZ (1) CZ303409B6 (hu)
DE (1) DE60103078T2 (hu)
DK (1) DK1326628T3 (hu)
EA (1) EA006137B1 (hu)
EE (1) EE05174B1 (hu)
ES (1) ES2217199T3 (hu)
HK (1) HK1062811A1 (hu)
HR (1) HRP20030215B1 (hu)
HU (1) HUP0302194A3 (hu)
IL (2) IL155178A0 (hu)
MX (1) MXPA03003008A (hu)
NO (1) NO330278B1 (hu)
PL (1) PL204231B1 (hu)
PT (1) PT1326628E (hu)
RS (1) RS50738B (hu)
SI (1) SI1326628T1 (hu)
SK (1) SK287523B6 (hu)
UA (1) UA77950C2 (hu)
WO (1) WO2002028419A2 (hu)
ZA (1) ZA200302315B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525089A (ja) 2001-12-17 2005-08-25 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ ケモカイン・アンタゴニストとして作用するケモカイン突然変異体
DE60303929T2 (de) * 2002-04-04 2006-08-10 Applied Research Systems Ars Holding N.V. Chemokin-muntanten mit verbesserter oraler bioverfügbarkeit
WO2004062688A2 (en) * 2002-12-23 2004-07-29 Applied Research Systems Ars Holding N.V. Use of cc-chemokine mutants against liver diseases
DE602004018014D1 (de) * 2003-10-22 2009-01-08 Serono Lab Cxcl8-antagonisten
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
DE60304435T2 (de) * 2004-01-19 2006-08-24 Ares Trading S.A. Verfahren zur Reinigung von in Bakterien exprimierten Proteinen
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
EP1760110B1 (en) * 2005-09-03 2011-11-02 Samsung SDI Co., Ltd. Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane
GB0614755D0 (en) 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
MX2010001307A (es) 2007-08-02 2010-07-30 Novimmune Sa Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
AU2011213559B2 (en) * 2010-02-08 2015-05-07 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same
CA3101052A1 (en) 2018-05-28 2019-12-05 ORION Biotechnology Switzerland Sarl Methods of inhibiting cerebral inflammation
WO2022093857A1 (en) * 2020-10-26 2022-05-05 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1998006751A1 (en) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
DE69832216T2 (de) * 1997-12-23 2006-05-24 Fondazione Centro San Raffaele Del Monte Tabor RANTES-Mutanten und therapeutische Anwendungen davon
AU2740900A (en) * 1999-01-29 2000-08-18 Millennium Pharmaceuticals, Inc. Method of treating demyelinating inflammatory disease using ccr1 antagonists

Also Published As

Publication number Publication date
SK4062003A3 (en) 2003-08-05
HRP20030215B1 (en) 2011-09-30
HK1062811A1 (en) 2004-11-26
HUP0302194A3 (en) 2005-12-28
CN1477969A (zh) 2004-02-25
PT1326628E (pt) 2004-09-30
AU1591902A (en) 2002-04-15
MXPA03003008A (es) 2003-07-14
ES2217199T3 (es) 2004-11-01
EP1326628B1 (en) 2004-04-28
NO330278B1 (no) 2011-03-21
WO2002028419A2 (en) 2002-04-11
SI1326628T1 (en) 2004-10-31
PL204231B1 (pl) 2009-12-31
RS50738B (sr) 2010-08-31
CA2423616C (en) 2010-03-16
WO2002028419A3 (en) 2002-06-13
NO20031525L (no) 2003-04-03
SK287523B6 (sk) 2011-01-04
DE60103078D1 (de) 2004-06-03
EA006137B1 (ru) 2005-10-27
NO20031525D0 (no) 2003-04-03
ATE265222T1 (de) 2004-05-15
DK1326628T3 (da) 2004-08-09
PL362350A1 (en) 2004-10-18
EA200300439A1 (ru) 2003-08-28
BR0114407A (pt) 2003-07-29
UA77950C2 (en) 2007-02-15
US7402303B2 (en) 2008-07-22
CZ2003947A3 (cs) 2003-11-12
US20040101509A1 (en) 2004-05-27
AU2002215919B2 (en) 2005-11-24
JP2004510426A (ja) 2004-04-08
IL155178A (en) 2009-07-20
JP3908165B2 (ja) 2007-04-25
AR030854A1 (es) 2003-09-03
BG107685A (bg) 2003-11-28
CA2423616A1 (en) 2002-04-11
HRP20030215A2 (en) 2005-02-28
CZ303409B6 (cs) 2012-09-05
IL155178A0 (en) 2003-11-23
DE60103078T2 (de) 2005-04-07
EE05174B1 (et) 2009-06-15
YU25703A (sh) 2006-05-25
EE200300139A (et) 2003-06-16
ZA200302315B (en) 2004-03-25
BG66137B1 (bg) 2011-07-29
EP1326628A2 (en) 2003-07-16
KR100837898B1 (ko) 2008-06-13
KR20030034238A (ko) 2003-05-01
CN1285381C (zh) 2006-11-22

Similar Documents

Publication Publication Date Title
HUP0302194A2 (hu) A kemokin-mutánsok a sclerosis multiplex kezelésében
IL214607A0 (en) 2,4-pyrimidinedinediamine compounds and their use in the manufacture of medicaments for the treatment of autoimmune disases
WO2005016893A3 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
CA2171882A1 (en) Inhibitors of .beta.-amyloid protein production
DK1091975T3 (da) Ny cyclosporin med forbedret aktivitetsprofil
HUP0203586A2 (hu) Szerotonin újrafelvétel inhibitorának, valamint 5-ht2c antagonistának, inverz agonistának vagy részleges agonistának a kombinációja
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
ATE200618T1 (de) Ssi tyrphostine und pharmazeutische zusammensetzungen
USD457718S1 (en) Toothpaste and toothbrush travel holder
Farooq et al. Community psychiatry in developing countries–a misnomer?
ATE230718T1 (de) Beta-alkoxyacrylate gegen malaria
EP1340536A3 (de) Verwendung von Formkörpern
CA2487331A1 (en) Anti-inflammatory compositions and methods of use
EP1199372A3 (en) Polymorphisms in the human P2X7 gene
RU2003124024A (ru) Штамм легионеллезного бактериофага ниим, активный в отношении legionella pneumophila, l. micdadei, l. dumoffii и l. bozemanii
TH42351EX (th) จอบหมุน
IT8819447A0 (it) Composizione di composti che migliorano l'attivita' analgesica, antipiretica e antinfiammatoria.
RU93008855A (ru) Сверло
EP1741722A3 (en) Polymorphisms in the human P2X7 gene
Kaidash et al. INVESTIGATION OF THE STRUCTURE AND PROPERTIES OF BORIDE COATINGS ON STEEL
Zamotaev et al. Side effects caused by antibacterial agents.
ITMI961070A0 (it) Prevenzione e trattamento delle infezioni virali topiche con perfluoropolietere o loro composizioni.
ITVI930089A0 (it) Macchina levigatrice, spazzolatrice e lucidatrice di profili continui in metallo prezioso o non, e di qualsiasi forma della loro sezione.
TH42347EX (th) เก้าอี้
TH60037EX (th) ปากกา

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished